close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc
Search

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

1.59 -2.45

Tugev "osta" hinnang

Hinna uuendus 4. mai 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.6

Max

1.6600000000000001

Põhinäitajad

By Trading Economics

Sissetulek

-2.8M

-16M

Müük

-8.7M

5.5M

Kasumimarginaal

-282.723

Töötajad

81

EBITDA

-4.2M

-15M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+134.97% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

64M

716M

Eelmine avamishind

4.04

Eelmine sulgemishind

1.59

Uudiste sentiment

By Acuity

45%

55%

135 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. mai 2026, 23:47 UTC

Tulu

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

DJ

Loe

3. mai 2026, 22:35 UTC

Tulu

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

DJ

Loe

3. mai 2026, 23:39 UTC

Market Talk

Gold Edge Higher Amid Signs of Resilience -- Market Talk

DJ

Loe

3. mai 2026, 23:34 UTC

Market Talk

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

DJ

Loe

3. mai 2026, 23:32 UTC

Tulu

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

DJ

Loe

3. mai 2026, 23:30 UTC

Market Talk

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

DJ

Loe

3. mai 2026, 23:20 UTC

Market Talk

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

DJ

Loe

3. mai 2026, 23:16 UTC

Omandamised, ülevõtmised, äriostud

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

DJ

Loe

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

DJ

Loe

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

DJ

Loe

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

DJ

Loe

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

DJ

Loe

3. mai 2026, 22:57 UTC

Omandamised, ülevõtmised, äriostud

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

DJ

Loe

3. mai 2026, 22:45 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

3. mai 2026, 22:45 UTC

Market Talk

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

DJ

Loe

3. mai 2026, 22:20 UTC

Tulu

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

DJ

Loe

3. mai 2026, 22:08 UTC

Tulu

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

DJ

Loe

3. mai 2026, 22:05 UTC

Tulu

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

DJ

Loe

3. mai 2026, 22:05 UTC

Tulu

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

DJ

Loe

3. mai 2026, 22:05 UTC

Tulu

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

DJ

Loe

3. mai 2026, 22:04 UTC

Tulu

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

DJ

Loe

3. mai 2026, 22:03 UTC

Tulu

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

DJ

Loe

3. mai 2026, 22:03 UTC

Tulu

NAB 1H Cash Return on Equity 8.5%>NAB.AU

DJ

Loe

3. mai 2026, 22:02 UTC

Tulu

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

DJ

Loe

3. mai 2026, 22:02 UTC

Tulu

NAB 1H Cash Earnings A$2.64B>NAB.AU

DJ

Loe

3. mai 2026, 22:02 UTC

Tulu

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

DJ

Loe

3. mai 2026, 22:01 UTC

Tulu

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

DJ

Loe

3. mai 2026, 22:01 UTC

Tulu

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

DJ

Loe

3. mai 2026, 22:01 UTC

Tulu

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

DJ

Loe

3. mai 2026, 15:06 UTC

Tulu

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

134.97% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD  134.97%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

3

Osta

1

Hoia

0

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Very Strong Bullish Evidence

All events are bullish.

Pikk perspektiiv

Weak Bearish Evidence

There is one bearish event.

Sentiment

By Acuity

135 / 347 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Muud aktsiad sektorist

JNJ

Johnson and Johnson

224.16

↓-1.45%

UNH

UnitedHealth Group Inc

370.76

↑ +0.47%

TMO

Thermo Fisher Scientific Inc

462.35

↓-1.48%

ISRG

Intuitive Surgical Inc

452.39

↓-1.14%

ABT

Abbott Laboratories

87.56

↓-2.18%
help-icon Live chat